Literature DB >> 7720709

RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.

J Y Chen1, S Penco, J Ostrowski, P Balaguer, M Pons, J E Starrett, P Reczek, P Chambon, H Gronemeyer.   

Abstract

Using retinoic acid receptor (RAR) reporter cells specific for either RAR alpha, beta or gamma, we have identified synthetic retinoids which specifically induce transactivation by RAR beta, while antagonizing RA-induced transactivation by RAR alpha and RAR gamma. Like RA, these synthetic retinoids allow all three RAR types to repress AP1 (c-Jun/c-Fos) activity, demonstrating that the transactivation and transrepression functions of RARs can be dissociated by properly designed ligands. Using AP1 reporter cells, we also show that glucocorticoids or vitamin D3, together with either RA or these 'dissociating' synthetic retinoids, can synergistically repress phorbol ester-induced AP1 activity. RA, but not these 'dissociating' retinoids, induced transcription of an interleukin-6 promoter-based reporter gene transiently transfected into HeLa cells together with RARs. Using Ki-ras-transformed 3T3 cells as a model system, we show that both RA and the 'dissociating' retinoids inhibit anchorage-independent cell proliferation, suggesting that retinoid-induced growth inhibition may be related to AP1 transrepression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720709      PMCID: PMC398196          DOI: 10.1002/j.1460-2075.1995.tb07102.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  106 in total

1.  Inhibition of tumor cell growth by retinoids.

Authors:  R Lotan; D Lotan; P G Sacks
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid.

Authors:  L Bonhomme; G Fredj; S Averous; A M Szekely; E Ecstein; B Trumbic; P Meyer; J M Lang; J L Misset; C Jasmin
Journal:  Ann Oncol       Date:  1991-03       Impact factor: 32.976

3.  Retinoic acid is a negative regulator of AP-1-responsive genes.

Authors:  R Schüle; P Rangarajan; N Yang; S Kliewer; L J Ransone; J Bolado; I M Verma; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Transformation suppressor activity of a Jun transcription factor lacking its activation domain.

Authors:  A Lloyd; N Yancheva; B Wasylyk
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

5.  Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia.

Authors:  F Lo Coco; G Avvisati; D Diverio; M C Petti; M Alcalay; P P Pandolfi; D Zangrilli; A Biondi; A Rambaldi; M L Moleti
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

6.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

Authors:  R P Warrell; S R Frankel; W H Miller; D A Scheinberg; L M Itri; W N Hittelman; R Vyas; M Andreeff; A Tafuri; A Jakubowski
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

7.  The retinoic acid alpha receptor gene is frequently disrupted in its 5' part in Chinese patients with acute promyelocytic leukemia.

Authors:  Z Chen; S J Chen; J H Tong; Y J Zhu; M E Huang; W C Wang; Y Wu; G L Sun; Z Y Wang; C J Larsen
Journal:  Leukemia       Date:  1991-04       Impact factor: 11.528

8.  Retinoic acid receptors and cellular retinoid binding proteins. II. Their differential pattern of transcription during early morphogenesis in mouse embryos.

Authors:  E Ruberte; P Dolle; P Chambon; G Morriss-Kay
Journal:  Development       Date:  1991-01       Impact factor: 6.868

9.  Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis.

Authors:  P Dollé; E Ruberte; P Leroy; G Morriss-Kay; P Chambon
Journal:  Development       Date:  1990-12       Impact factor: 6.868

10.  Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors.

Authors:  L Shemshedini; R Knauthe; P Sassone-Corsi; A Pornon; H Gronemeyer
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  48 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

Review 2.  Role of retinoid receptors in the prevention and treatment of breast cancer.

Authors:  L M Yang; C Tin-U; K Wu; P Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts.

Authors:  R Taneja; B Roy; J L Plassat; C F Zusi; J Ostrowski; P R Reczek; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers.

Authors:  V Vivat; C Zechel; J M Wurtz; W Bourguet; H Kagechika; H Umemiya; K Shudo; D Moras; H Gronemeyer; P Chambon
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

Review 5.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

6.  Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.

Authors:  Virginie Nahoum; Efrén Pérez; Pierre Germain; Fátima Rodríguez-Barrios; Fabio Manzo; Sabrina Kammerer; Geraldine Lemaire; Oliver Hirsch; Catherine A Royer; Hinrich Gronemeyer; Angel R de Lera; William Bourguet
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-18       Impact factor: 11.205

7.  Pharmacological activity of retinoic acid receptor alpha-selective antagonists in vitro and in vivo.

Authors:  Sanny S W Chung; Rebecca A D Cuellar; Xiangyuan Wang; Peter R Reczek; Gunda I Georg; Debra J Wolgemuth
Journal:  ACS Med Chem Lett       Date:  2013-05-09       Impact factor: 4.345

8.  A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains.

Authors:  I Zamir; H P Harding; G B Atkins; A Hörlein; C K Glass; M G Rosenfeld; M A Lazar
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Krüppel-like factor 5 mediates the transforming activity of oncogenic H-Ras.

Authors:  Mandayam O Nandan; Hong S Yoon; Weidong Zhao; Lillian A Ouko; Sengthong Chanchevalap; Vincent W Yang
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

10.  The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor.

Authors:  Takahiro Ishizuka; Mitchell A Lazar
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.